Improving the Survival in Patients with Decompensated CirrhosisView this Special Issue
Review Article | Open Access
Treatment of Decompensated Alcoholic Liver Disease
Alcoholic liver disease (ALD) is a spectrum ranging from simple hepatic steatosis to alcoholic hepatitis and cirrhosis. Patients with severe alcoholic hepatitis can have clinical presentation almost similar to those with decompensated cirrhosis. Scoring with models like Maddrey discriminant function, a model for end-stage liver disease, Glasgow alcoholic hepatitis score, and Lille model are helpful in prognosticating patients with ALD. One of the first therapeutic goals in ALD is to induce alcohol withdrawal with psychotherapy or drugs. Most studies have shown that nutritional therapy improves liver function and histology in patients with ALD. The rationale for using glucocorticoids is to block cytotoxic and inflammatory pathways in patients with severe alcoholic hepatitis. Pentoxifylline, a tumor necrosis factor alpha (TNFα) suppressor, and infliximab, an anti-TNFα mouse/human chimeric antibody, has been extensively studied in patients with alcoholic hepatitis. Liver transplantation remains the definitive therapy for decompensated cirrhosis/alcoholic hepatitis despite the issues of recidivism, poor compliance with postoperative care, and being a self-inflicted disease.
Alcohol is a major risk factor for chronic disease burden all over the world. Alcohol abusers and patients with alcoholic liver disease (ALD) usually suffer negative consequences from drinking such as significant financial burden, unemployment, loss of family, accidental injury, or death . Alcoholism is a physical dependence that includes impaired control, craving, development of tolerance, and development of withdrawal symptoms on abstinence.
ALD is a spectrum that ranges from fatty liver to alcoholic steatohepatitis (ASH) and eventually cirrhosis. Simple hepatic steatosis is the commonest histological finding and occurs in 90% of heavy drinkers but is rapidly reversible with abstinence. Alcoholic hepatitis or ASH occurs in up to 35% of heavy drinkers and is usually a precursor of cirrhosis .
Epidemiological data suggest that a threshold of 80 g of daily alcohol in a male and 20–40 g in a female for an average of 10 to 12 years is necessary for causing significant alcohol-induced liver injury [3, 4]. However, only a minority of individuals who consume alcohol in excess develop significant ALD. Synergistic factors such as chronic hepatitis C, obesity, and genetic factors may accelerate the development of ALD even at lower doses of alcohol consumption.
ASH is a clinic-pathological syndrome that denotes hepatocellular necrosis and inflammation. The clinical spectrum can range from being asymptomatic to developing overt liver failure. There may be low-grade fever, jaundice, leukocytosis, and mild elevation of transaminases. Histological features of ASH include the presence of parenchymal necrosis, Mallory bodies, and a perivenular neutrophilic infiltrate. Other features that are commonly present include bridging necrosis, fatty changes, bile duct proliferation, cholestasis, and perivenular fibrosis. Liver biopsy as a means of prognostication in alcoholic hepatitis has mostly been replaced with less invasive scoring systems. Patients with severe alcoholic hepatitis can have clinical presentation almost similar to those with decompensated cirrhosis, and it may become difficult to establish if such patients have associated cirrhosis or not. But histologically, the majority of patients with severe alcoholic hepatitis have either significant fibrosis or cirrhosis liver. And alcoholic hepatitis with underlying cirrhosis is one of the most important causes of acute on chronic liver failure (ACLF) .
2. Prognostic Models in Patients with Alcoholic Liver Disease
2.1. Discriminant Function
The Maddrey discriminant function (DF) score remains the most commonly used predictive model and was developed to facilitate the assessment of response in a clinical trial of corticosteroids in patients with alcoholic hepatitis . Modified DF is calculated as = 4.6 × (prolongation of prothrombin time in seconds) + Serum bilirubin (mg/dL). A modified DF score >32 in the presence of hepatic encephalopathy predicts >50% mortality within 28 days in patients with alcoholic hepatitis [7, 8]. However, fatal outcomes have also been known to occur in patients with modified DF score <32, and this low specificity has suggested a need for alternative scoring systems.
2.2. Model for End-Stage Liver Disease (MELD)
MELD score was initially developed to predict survival in patients with cirrhosis undergoing transjugular intrahepatic portosystemic shunting (TIPSS). However, it has been found to predict mortality in ASH, and a MELD score ≥21 (within 24 hours of presentation) is a good predictor of 90-day mortality in these patients . MELD and modified DF scores (calculated within 24 hours of presentation) are equivalent in predicting 30- and 90-day mortality in patients with alcoholic hepatitis .
2.3. Glasgow Alcoholic Hepatitis Score (GAHS)
GAHS was developed in an effort to overcome the low specificity of the Maddrey DF and lack of an optimal predictive cutoff point for the MELD score. GAHS is a composite scoring system based on age, serum bilirubin, blood urea nitrogen, PT, and the peripheral leucocyte count. GAHS ≥9 is a predictor of mortality and is more accurate than DF in predicting both 28- and 84-day mortality but is equivalent to MELD in predicting 28-day mortality .
2.4. Lille Model
The Lille model incorporates age, renal insufficiency, albumin, PT, bilirubin, and the evolution of bilirubin on day 7 to predict 6-month mortality in patients with severe alcoholic hepatitis who have received corticosteroid therapy .
A recent study showed that among the various prognostic scores for acute alcoholic hepatitis (Lille, Glasgow, and Maddrey scores) and cirrhosis (MELD, MELD-Na, and Child-Turcotte-Pugh) in ALD patients treated with corticosteroids, Lille score ≥0.45 and GAHS ≥9 were the most accurate models for the prediction of mortality . Although the components may be different in each of these scores, they help the physicians to identify a subset of patients with higher mortality and requiring aggressive management.
3. Treatment of Alcoholic Liver Disease
3.1. General Management
One of the first therapeutic goals of patient management in patients with ALD is to induce alcohol withdrawal. The administration of fluid, calories, vitamins, and minerals is usually required. However, overhydration should be avoided, as this can worsen ascites and can precipitate variceal bleed. Vitamin K is usually administered to patients who have a prolonged prothrombin time, even though this regimen is typically ineffective because coagulopathy reflects severity of underlying liver disease. Correction of the coagulopathy with fresh frozen plasma is not recommended in the absence of active hemorrhage, because this treatment might increase the risk of variceal hemorrhage in a patient with portal hypertension. Admission to a critical care unit should be considered for unstable patients, and airway protection should be assured in a patient with hepatic encephalopathy.
Abstinence is the cornerstone of therapy in the management of ALD. Ideally, this includes rehabilitation with a multidisciplinary approach. If abstinence is achieved, clinical and histological improvement occurs, even if the patient is already cirrhotic [14–17]. Both psychological and pharmacological approaches can be used to treat alcohol dependence. Psychological interventions involve strategies to educate and inform patients about the nature of their problem and provide them with advice on how to change their behavior. Psychosocial treatments such as cognitive behavioral therapy and motivational enhancement therapy have been shown to reduce alcohol intake in alcohol-dependent patients .
As an addition to psychological therapies, many patients might benefit from pharmacological therapy. Both acamprosate and naltrexone have been demonstrated to reduce the number of drinking days and increase abstinence rates in randomized controlled trials . Acamprosate, unlike naltrexone, is well tolerated except in patients with Child C cirrhosis and its benefit seems to persist for at least 1 year after treatment withdrawal. Disulfiram, an inhibitor of acetaldehyde dehydrogenase, has been used for many years in the management of alcohol-dependent patients, although with conflicting results.
Patients with ALD are malnourished for a number of reasons, including malabsorption, the induction of a catabolic state, and the replacement of calories with alcohol. Protein-caloric malnutrition has also been demonstrated to correlate with short-term and long-term mortality in alcoholics. Hence, malnutrition should be actively sought in such patients, and replacement should be commenced accordingly. The efficacy of nutritional therapy in ASH has been evaluated in numerous clinical trials. Although various results have been reported, most studies have shown that nutritional therapy improves liver function and histology. Enteral feeding is preferred to parenteral nutrition. Although protein ingestion is a theoretical risk factor for the development of hepatic encephalopathy, protein feeding is well tolerated, and protein should not be routinely restricted in patients with ASH.
Two randomized controlled trials have looked at the effects of nutritional therapy. The first study compared enteral tube feeding of an energy-dense formula (>2,000 kcal daily) with an isocaloric standard oral diet in 35 randomly allocated, severely malnourished, cirrhotic patients. In-hospital mortality was significantly lower in the enteral group (12% versus 47%) . The second study which compared enteral feeding with steroids in 71 patients with acute, severe ASH found that there was no difference in mortality between the groups during the 28-day treatment period. However, the mortality rate was lower in the enterally fed group in the year following treatment . In summary, nutritional supplementation could have a role in the improvement of medium-term to long-term survival in patients with severe ASH. The American College of Gastroenterology guidelines recommend 1.2 to 1.5 g/kg of protein and 35 to 40 kcal/kg of body weight for patients with ALD .
Glucocorticoids are the most intensely studied and yet most hotly debated treatment for acute alcoholic hepatitis. The rationale for glucocorticoid use is to block cytotoxic and inflammatory pathways in alcoholic hepatitis. Glucocorticoids have been shown to decrease proinflammatory cytokines and intercellular cell adhesion molecule 1 expression and inhibit neutrophil activation and have demonstrated short-term histological improvement in patients with alcoholic hepatitis.
Results from trials of glucocorticoids for ALD are variable and depend on the nature of the trial and the group of patients recruited as the study population. Even among glucocorticoids trials with beneficial results, enrolled subjects were heterogeneous with variable definitions of randomization and blinding and without homogeneous inclusion or exclusion criteria. Different types of steroids for different durations and different criteria were used for treatment. Steroid use in alcoholic hepatitis raises the risk of infection in an already immunocompromised host. Some trials have demonstrated higher mortality in the glucocorticoid group compared to the placebo group [23–26]. Associated with this higher mortality, a greater incidence of fungal infections among patients receiving glucocorticoids has been reported by some authors . A meta-analysis on this subject, published in 1990, demonstrated a protective effect of glucocorticoids in high quality trials. This was especially so in studies that excluded patients with gastrointestinal bleeding but included those with hepatic encephalopathy . But another meta-analysis by Christensen and Gluud found no benefit once they attempted to control for confounders . A subsequent reanalysis of the same 3 randomized, controlled trials in Christiansen and Gluud’s meta-analysis, which pooled raw data from more than 200 patients with modified DF ≥32, found a 28-day survival benefit of glucocorticoids (85%) versus placebo (65%). In patients with modified DF ≥32, treatment with glucocorticoids improved short-term (28-day) survival, with mortality decreasing from 35% in controls to 15% with steroids. Conversely, patients with modified DF <32 had a >90% survival rate without steroids. The number of patients who needed to be treated to save 1 patient was 5 . Another meta-analysis of 15 trials with 721 randomized patients reported that the evidence in favor of glucocorticoids was based on heterogeneous trials of low quality . Recently using individual patient data from more than 400 patients, Mathurin et al. demonstrated improved survival with corticosteroid treatment. Patients were classified as complete responders (Lille score ≤0.16; ≤35th percentile), partial responders (Lille score 0.16–0.56; 35th–70th percentile), and null responders (Lille ≥0.56; ≥70th percentile). 28-day survival was strongly associated with these groupings (91% versus 79% versus 53%, ). Corticosteroids had a significant effect on 28-day survival in complete responders and in partial responders but not in null responders . The long-term benefit of steroids is difficult to assess as the various trials had differing follow-up periods, and unless the patient abstains from alcohol completely, alcoholic hepatitis is likely to recur. The survival benefit of corticosteroid therapy has not been found to persist beyond 1 year.
Despite having 13 randomized controlled trials and 6 meta-analyses of steroids as a treatment for ASH, concerns over their use continue. Although corticosteroids are probably beneficial in patients with severe disease, mortality on treatment remains high, particularly when renal impairment is present, and treatment is contraindicated in a relatively large number of patients with concomitant infection and gastrointestinal bleeding.
3.5. Antitumor Necrosis Factor Alpha Treatment
Elevated tumor necrosis factor alpha (TNFα) levels have been found to be predictive of poor survival in patients with alcoholic hepatitis. Pentoxifylline is a nonselective phosphor-di-esterase inhibitor and a TNFα suppressor. In 1991, a study of pentoxifylline for severe alcoholic hepatitis (DF ≥ 32) reported a reduction in the development of hepatorenal syndrome and mortality in comparison with placebo . A subsequent study of 101 patients from the same center supported the earlier findings, demonstrating a 40% reduction in mortality in comparison with placebo. The number needed to treat to prevent 1 death was 4.7. However, in this study, there was no demonstrable improvement in routine liver function tests or liver histology and the better survival was predominantly due to decreased incidence of hepatorenal syndrome .
In another study, 29 patients who did not respond to corticosteroids (identified by an absence of an early decline in bilirubin) were switched to pentoxifylline for 28 days and compared to 58 other matched patients who persisted with corticosteroid therapy. No survival benefit was observed with pentoxifylline at 2 months . Thus, although some data suggest a benefit with pentoxifylline in alcoholic hepatitis, it is unclear whether its benefit extends beyond possibly preventing hepatorenal syndrome.
Infliximab is an anti-TNFα mouse/human chimeric antibody and has been extensively studied in alcoholic hepatitis. Early reports were encouraging, demonstrating improved survival rates, improved Maddrey scores, or improved laboratory parameters. However, the largest randomized, controlled trial to date, which enrolled 36 patients and compared a combination of prednisolone (40 mg/day) and infliximab (10 mg/kg 3 times per week in weeks 0, 2, and 4) to prednisolone and placebo in alcoholic hepatitis was terminated prematurely . More deaths had occurred in the group treated with prednisolone and infliximab. Whether this risk was related to the higher doses of infliximab used, more ill patients being recruited in this trial in comparison with earlier studies, the combined use of prednisolone and infliximab, or the possible unsuitability of infliximab for the treatment of alcoholic hepatitis is still debatable.
A small, uncontrolled study evaluated the use of etanercept in 13 patients with moderate to severe alcoholic hepatitis. Two patients died within 32 days, and 3 developed serious adverse events (infection, gastrointestinal bleeding, and hepatorenal syndrome) mandating withdrawal of the drug . A more recent multicenter, randomized, double-blind, placebo-controlled study of etanercept in 48 patients with severe alcoholic hepatitis (defined as MELD ≥ 15) found no difference in the 1-month mortality rates in the 2 groups on an intention-to-treat analysis . Alarmingly, the 6-month mortality in the etanercept group was significantly higher in comparison with the controls. Rates of serious adverse infectious events were also significantly higher in the etanercept group. These results have considerably dampened the enthusiasm for using anti-TNFα agents in patients with severe ASH.
3.6. Antioxidant Cocktails
Antioxidants have been tried in alcoholic hepatitis as oxidative stress is a key factor in its pathogenesis. However, results have failed to show any convincing benefit from their use. Phillips et al., who compared corticosteroids to an antioxidant cocktail (β-carotene, vitamins C and E, selenium, methionine, allopurinol, desferrioxamine, and N-acetylcysteine), reported inferior survival rates in comparison with corticosteroids at 30 days . Another study stratified patients with severe alcoholic hepatitis by gender and corticosteroid treatment. The active group received a loading dose of N-acetylcysteine (150 mg/kg followed by 100 mg/kg/day for 1 week) and daily doses of vitamins A and E, biotin, selenium, zinc, manganese, copper, magnesium, folic acid, and coenzyme Q for 6 months. Antioxidant therapy showed no benefit, either alone or in combination with corticosteroids . A more recent study of 87 patients with severe alcoholic hepatitis (defined as modified Maddrey DF ≥32) randomized patients to receive either corticosteroids with N-acetylcysteine infusion for 5 days or corticosteroids alone . Although patients in the N-acetylcysteine group had better 1-month survivals, this effect did not persist at 3 and 6 months.
3.7. S-Adenosyl Methionine
S-Adenosyl methionine (SAMe) is a precursor of glutathione that theoretically might be protective in alcohol-induced liver injury. In a Cochrane database review of 9 randomized trials that combined a heterogeneous sample of 434 patients with ALD, SAMe failed to show a survival benefit . Only 1 trial of 62 patients deemed to have adequate methodology and outcome reporting and good quality suggested benefit (improved survival and delay to liver transplantation) with 2 years of SAMe treatment for Child’s class A and B alcoholic cirrhosis .
3.8. Treatment of Hepatorenal Syndrome Associated with Alcoholic Hepatitis
In patients with severe ASH, the development of renal failure is associated with a survival of less than 10% even with intensive management. The most significant advance in the management of patients with advanced liver disease over the past decade has been the introduction of albumin infusions combined with splanchnic vasoconstrictor agents for patients with hepatorenal syndrome. Although no randomized trials have specifically examined this form of therapy in patients with ASH, the previously reported high mortality in ASH patients with hepatorenal syndrome suggests that albumin infusions combined with splanchnic vasoconstrictor agents would have a significant and beneficial effect on patient survival. The usefulness of pentoxyfylline in this clinical setting has been mentioned earlier.
3.9. Liver Transplantation in ALD
Orthotopic liver transplantation (OLT) remains the definitive therapy for decompensated cirrhosis due to ALD despite continued alcohol abstinence. Short-term (1- to 7-year) graft survival and patient survival remain at par with, if not superior to, survival with non-ALD if the patient remains abstinent. Bellamy et al. reported that in 123 patients who were transplanted, patient survival at 1, 5, and 7 years was 84%, 72%, and 64%, respectively. Graft survival was 81%, 66%, and 50%, respectively, over the same period . The 1- and 5-year patient and graft survival rates for all patients with cirrhosis were 86.9%/73.4% and 82.4%/67.4%, respectively .
However, OLT for ALD patients continues to fuel controversy, including issues of recidivism, potentially poor compliance with postoperative care, and inherent biases against alcoholics, such as concern about using scarce organs for what is often perceived to be a self-inflicted disease.
DiMartini et al.’s prospective study of alcoholic recipients found that 22% had used some alcohol by the end of the first year post-OLT and 42% had by 5 years, of whom 26% had a binge drinking pattern . Such a wide range of relapse rates may stem from varying definitions of recidivism and methods of eliciting alcohol consumption data. Most studies addressing recidivism in the past 20 years have used the “any use” definition of alcohol relapse. However, a return to drinking does not necessarily mean excessive drinking. Furthermore, Fabrega et al.’s report of patients who had returned to drinking revealed no decreased compliance with other medical care, including immunosuppressant therapy . Pfitzmann et al. stratified relapsers into slips and harmful drinking, revealing significantly worse 5- and 10-year survival rates (69.5% and 20%) among “harmful” drinkers versus abstainers (90.3% and 81.5%) .
A major focus in determining candidacy for liver transplantation in ALD has been identifying factors to predict posttransplant recidivism. Pretransplant duration of abstinence from alcohol was the first predictive factor analyzed. Other medical and social variables can be associated with high relapse rates, including tobacco consumption, noncompliance to follow-up clinic visits, and mental illness. A 2008 meta-analysis of 50 studies looking at predictors of recidivism found 3 significant, albeit modest, variables: a poor social support system, a family history of alcohol abuse/dependence, and pretransplant abstinence of 6 months or less .
Pre-OLT abstinence, especially the 6-month rule, remains contentious. Studies over the years have provided convincing data for and against the 6-month abstinence requirement. Lucey et al. suggested that this 6-month period of abstinence would allow the native liver to recover with medical management and possibly obviate transplantation . However, this minimal period of abstinence is sometimes waived if the patient is deemed too ill to survive beyond 6 months without a liver transplant. One study showed that recovery in decompensated alcoholic cirrhosis by alcohol abstinence can be predicted within 3 months of abstinence by the monitoring of clinical signs via the Child-Pugh scoring system (serum bilirubin, albumin, international normalized ratio, ascites, and hepatic encephalopathy) . This study by Veldt et al. found that although such improvement in liver function can take place within 3 months of abstinence, some abstinent patients die within 6 months; this has led some authors to suggest reducing the period of abstinence from 6 to 3 months. Yet, abstinence less than 12 months was recently identified as a significant risk factor for relapse in a large retrospective study of OLT recipients .
Finally, an increasing concern of late is the high risk for de novo malignancies in long-term survivors transplanted for ALD. Although posttransplantation lymphoproliferative disorder and nonmelanoma skin cancer remain the most common malignancies after liver transplantation, the incidence of esophageal cancer is significantly increased in patients with alcohol as the etiology of end-stage liver disease. Duvoux et al.’s prospective study showed a significantly higher incidence of malignancies in patients with ALD compared to those with non-ALD etiologies . They also detected squamous cell carcinoma of the oropharynx or esophagus only in recipients transplanted for ALD. Risk factors undoubtedly include the cumulative effects of alcohol and, in most cases, smoking with posttransplant immunosuppression. Thus, regular ear, nose, and throat examinations appear justified in patients transplanted for ALD.
- H. Singh, B. Masih, S. K. Satpathy, A. Duseja, and Y. Chawla, “Financial burden of alcohol abuse in patients with alcoholic liver disease,” Tropical Gastroenterology, vol. 22, no. 3, p. 172, 2001.
- M. Adachi and D. A. Brenner, “Clinical syndromes of alcoholic liver disease,” Digestive Diseases, vol. 23, no. 3-4, pp. 255–263, 2005.
- W. Lelbach, “Epidemiology of alcoholic liver disease,” in Progress in Liver Disease, H. Popper and F. Schaffner, Eds., vol. 5, pp. 494–515, Grune and Stratton, New York, NY, USA, 1976.
- W. Lelbach, “Quantitative aspects of drinking in alcoholic liver cirrhosis,” in Alcoholic Liver Pathology, H. M. Khanna, Y. Israel, and H. Kalant, Eds., pp. 1–18, Toronto Addiction Research Foundation of Ontario, Toronto, Canada, 1975.
- A. Duseja, Y. K. Chawla, R. K. Dhiman, A. Kumar, N. Choudhary, and S. Taneja, “Non-hepatic insults are common acute precipitants in patients with acute on chronic liver failure (ACLF),” Digestive Diseases and Sciences, vol. 55, pp. 3188–3192, 2010.
- W. C. Maddrey, J. K. Boitnott, M. S. Bedine, F. L. Weber Jr., E. Mezey, and R. I. White Jr., “Corticosteroid therapy of alcoholic hepatitis,” Gastroenterology, vol. 75, pp. 193–199, 1978.
- R. L. Carithers Jr., H. F. Herlong, A. M. Diehl et al., “Methylprednisolone therapy in patients with severe alcoholic hepatitis. A randomized multicenter trial,” Annals of Internal Medicine, vol. 110, no. 9, pp. 685–690, 1989.
- M. J. Ramond, T. Poynard, B. Rueff et al., “A randomized trial of prednisolone in patients with severe alcoholic hepatitis,” The New England Journal of Medicine, vol. 326, no. 8, pp. 507–512, 1992.
- W. Dunn, L. H. Jamil, L. S. Brown et al., “MELD accurately predicts mortality in patients with alcoholic hepatitis,” Hepatology, vol. 41, no. 2, pp. 353–358, 2005.
- W. Srikureja, N. L. Kyulo, B. A. Runyon, and K. Q. Hu, “MELD score is a better prognostic model than Child-Turcotte-Pugh score or Discriminant Function score in patients with alcoholic hepatitis,” Journal of Hepatology, vol. 42, no. 5, pp. 700–706, 2005.
- E. H. Forrest, C. D. Evans, S. Stewart et al., “Analysis of factors predictive of mortality in alcoholic hepatitis and derivation and validation of the Glasgow alcoholic hepatitis score,” Gut, vol. 54, no. 8, pp. 1174–1179, 2005.
- A. Louvet, S. Naveau, M. Abdelnour et al., “The Lille model: a new tool for therapeutic strategy in patients with severe alcoholic hepatitis treated with steroids,” Hepatology, vol. 45, no. 6, pp. 1348–1354, 2007.
- J. Boursier, M. Demy, V. Moal et al., “Prediction of outcome in patients with severe acute alcoholic hepatitis treated by corticosteroids,” Hepatology, vol. 48, p. S636A, 2008.
- T. B. Reynolds, H. M. Geller, O. T. Kuzma, and A. G. Redeker, “Spontaneous decrease in portal pressure with clinical improvement in cirrhosis,” The New England Journal of Medicine, vol. 263, pp. 734–739, 1960.
- J. F. Alexander, M. W. Lischner, and J. T. Galambos, “Natural history of alcoholic hepatitis. II. The long-term prognosis,” The American Journal of Gastroenterology, vol. 56, no. 6, pp. 515–525, 1971.
- W. J. Powell Jr. and G. Klatskin, “Duration of survival in patients with Laennec's cirrhosis. Influence of alcohol withdrawal, and possible effects of recent changes in general management of the disease,” The American Journal of Medicine, vol. 44, no. 3, pp. 406–420, 1968.
- O. Niemela, J. Risteli, J. E. Blake, L. Risteli, K. V. Compton, and H. Orrego, “Markers of fibrogenesis and basement membrane formation in alcoholic liver disease. Relation to severity, presence of hepatitis, and alcohol intake,” Gastroenterology, vol. 98, no. 6, pp. 1612–1619, 1990.
- A. Moyer, J. W. Finney, C. E. Swearingen, and P. Vergun, “Brief interventions for alcohol problems: a meta-analytic review of controlled investigations in treatment-seeking and non-treatment-seeking populations,” Addiction, vol. 97, no. 3, pp. 279–292, 2002.
- J. C. Garbutt, S. L. West, T. S. Carey, K. N. Lohr, and F. T. Crews, “Pharmacological treatment of alcohol dependence: a review of the evidence,” Journal of the American Medical Association, vol. 281, no. 14, pp. 1318–1325, 1999.
- E. Cabre, F. Gonzalez-Huix, A. Abad-Lacruz et al., “Effect of total enteral nutrition on the short-term outcome of severely malnourished cirrhotics. A randomized controlled trial,” Gastroenterology, vol. 98, no. 3, pp. 715–720, 1990.
- E. Cabré, P. Rodríguez-Iglesias, J. Caballería et al., “Short- and long-term outcome of severe alcohol-induced hepatitis treated with steroids or enteral nutrition: a multicenter randomized trial,” Hepatology, vol. 32, no. 1, pp. 36–42, 2000.
- A. J. McCullough and J. F. O'Connor, “Alcoholic liver disease: proposed recommendations for the American College of Gastroenterology,” The American Journal of Gastroenterology, vol. 93, no. 11, pp. 2022–2036, 1998.
- C. L. Mendenhall, S. Anderson, P. Garcia-Pont et al., “Short-term and long-term survival in patients with alcoholic hepatitis treated with oxandrolone and prednisolone,” The New England Journal of Medicine, vol. 311, no. 23, pp. 1464–1470, 1984.
- J. B. Shumaker, R. H. Resnick, J. T. Galambos et al., “A controlled trial of 6-methyl-prednisolone in acute alcoholic hepatitis. With a note on published results in encephalopathic patients,” The American Journal of Gastroenterology, vol. 69, pp. 443–449, 1978.
- B. L. Blitzer, M. G. Mutchnick, P. H. Joshi et al., “Adrenocorticosteroid therapy in alcoholic hepatitis. A prospective, double blind randomized study,” The American Journal of Digestive Diseases, vol. 22, no. 6, pp. 477–484, 1977.
- A. Theodossi, A. L. Eddleston, and R. Williams, “Controlled trial of methylprednisolone therapy in severe acute alcoholic hepatitis,” Gut, vol. 23, no. 1, pp. 75–79, 1982.
- T. F. Imperiale and A. J. McCullough, “Do corticosteroids reduce mortality from alcoholic hepatitis? A meta-analysis of the randomized trials,” Annals of Internal Medicine, vol. 113, no. 4, pp. 299–307, 1990.
- E. Christensen and C. Gluud, “Glucocorticoids are ineffective in alcoholic hepatitis: a meta-analysis adjusting for confounding variables,” Gut, vol. 37, no. 1, pp. 113–118, 1995.
- P. Mathurin, C. L. Mendenhall, R. L. Carithers Jr. et al., “Corticosteroids improve short-term survival in patients with severe alcoholic hepatitis (AH): individual data analysis of the last three randomized placebo controlled double blind trials of corticosteroids in severe AH,” Journal of Hepatology, vol. 36, no. 4, pp. 480–487, 2002.
- A. Rambaldi, H. H. Saconato, E. Christensen, K. Thorlund, J. Wetterslev, and C. Gluud, “Systematic review: glucocorticosteroids for alcoholic hepatitis—a Cochrane Hepato-Biliary Group systematic review with meta-analyses and trial sequential analyses of randomized clinical trials,” Alimentary Pharmacology and Therapeutics, vol. 27, no. 12, pp. 1167–1178, 2008.
- P. Mathurin, J. O'Grady, R. L. Carithers et al., “Corticosteroids improve 28-day survival in patients with severe alcoholic hepatitis: meta analysis of individual patient data,” Gut, vol. 60, pp. 255–260, 2011.
- J. G. McHutchison, B. A. Runyon, J. O. Draguesku et al., “Pentoxifylline may prevent renal impairment (hepatorenal syndrome) in severe acute alcoholic hepatitis,” Hepatology, vol. 14, p. S96A, 1991.
- E. Akriviadis, R. Botla, W. Briggs, S. Han, T. Reynolds, and O. Shakil, “Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: a double-blind, placebo-controlled trial,” Gastroenterology, vol. 119, no. 6, pp. 1637–1648, 2000.
- A. Louvet, E. Diaz, S. Dharancy et al., “Early switch to pentoxifylline in patients with severe alcoholic hepatitis is inefficient in non-responders to corticosteroids,” Journal of Hepatology, vol. 48, no. 3, pp. 465–470, 2008.
- S. Naveau, S. Chollet-Martin, S. Dharancy et al., “A double-blind randomized controlled trial of infliximab associated with prednisolone in acute alcoholic hepatitis,” Hepatology, vol. 39, no. 5, pp. 1390–1397, 2004.
- K. V. Menon, L. Stadheim, P. S. Kamath et al., “A pilot study of the safety and tolerability of etanercept in patients with alcoholic hepatitis,” The American Journal of Gastroenterology, vol. 99, no. 2, pp. 255–260, 2004.
- N. C. Boetticher, C. J. Peine, P. Kwo et al., “A randomized, double-blinded, placebo-controlled multicenter trial of etanercept in the treatment of alcoholic hepatitis,” Gastroenterology, vol. 135, no. 6, pp. 1953–1960, 2008.
- M. Phillips, H. Curtis, B. Portmann, N. Donaldson, A. Bomford, and J. O'Grady, “Antioxidants versus corticosteroids in the treatment of severe alcoholic hepatitis—a randomised clinical trial,” Journal of Hepatology, vol. 44, no. 4, pp. 784–790, 2006.
- S. Stewart, M. Prince, M. Bassendine et al., “A randomized trial of antioxidant therapy alone or with corticosteroids in acute alcoholic hepatitis,” Journal of Hepatology, vol. 47, no. 2, pp. 277–283, 2007.
- E. Nguyen-Khac, T. Thevenot, M. Piquet et al., “Treatment of severe alcoholic hepatitis with corticosteroids plus N-acetylcysteine versus corticoids: planned interim analysis of a multicenter, controlled, randomized trial,” Hepatology, vol. 48, p. S634A, 2008.
- A. Rambaldi and C. Gluud, “S-adenosyl-L-methionine for alcoholic liver diseases,” Cochrane Database of Systematic Reviews, no. 2, article CD002235, 2006.
- J. M. Mato, J. Camara, J. Fernandez de Paz et al., “S-adenosylmethionine in alcoholic liver cirrhosis: a randomized, placebo-controlled, double-blind, multicenter clinical trial,” Journal of Hepatology, vol. 30, pp. 1081–1089, 1999.
- C. O. Bellamy, A. M. DiMartini, K. Ruppert et al., “Liver transplantation for alcoholic cirrhosis: long term follow-up and impact of disease recurrence,” Transplantation, vol. 72, no. 4, pp. 619–626, 2001.
- “OPTN/SRTR Annual Report, 2008,” http://optn.transplant.hrsa.gov/ar2008/Chapter_IV_AR_CD.htm?cp=5.
- A. DiMartini, N. Day, M. A. Dew et al., “Alcohol consumption patterns and predictors of use following liver transplantation for alcoholic liver disease,” Liver Transplantation, vol. 12, no. 5, pp. 813–820, 2006.
- E. Fabrega, J. Crespo, F. Casafont et al., “Alcoholic recidivism after liver transplantation for alcoholic cirrhosis,” Journal of Clinical Gastroenterology, vol. 26, pp. 204–206, 1998.
- R. Pfitzmann, J. Schwenzer, N. Rayes, D. Seehofer, R. Neuhaus, and N. C. Nüssler, “Long-term survival and predictors of relapse after orthotopic liver transplantation for alcoholic liver disease,” Liver Transplantation, vol. 13, no. 2, pp. 197–205, 2007.
- M. A. Dew, A. F. DiMartini, J. Steel et al., “Meta-analysis of risk for relapse to susbtance use after transplantation of the liver or other solid organs,” Liver Transplantation, vol. 14, no. 2, pp. 159–172, 2008.
- M. R. Lucey, K. A. Brown, G. T. Everson et al., “Minimal criteria for placement of adults on the liver transplant waiting list: a report of a national conference organized by the American Society of Transplant Physicians and the American Association for the Study of Liver Diseases,” Liver Transplantation and Surgery, vol. 3, no. 6, pp. 628–637, 1997.
- B. J. Veldt, F. Lainé, A. Guillygomarch et al., “Indication of liver transplantation in severe alcoholic liver cirrhosis: quantitative evaluation and optimal timing,” Journal of Hepatology, vol. 36, no. 1, pp. 93–98, 2002.
- C. Duvoux, I. Delacroix, J. P. Richardet et al., “Increased incidence of oropharyngeal squamous cell carcinomas after liver transplantation for alcoholic cirrhosis,” Transplantation, vol. 67, pp. 418–421, 1999.
Copyright © 2011 John Menachery and Ajay Duseja. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.